Novo Nordisk shares fell 20% after the company cut full-year sales growth guidance to 8% to 14% from 13% to 21% and appointed Maziar Mike Doustdar as CEO following the sudden ousting of Lars Fruergaard Jørgensen. The lowered outlook reflects softer growth expectations across its product portfolio. The stock partially recovered from an initial 26% intraday drop but remained sharply lower.